FDA Approves Bavencio (avelumab) Plus Inlyta (axitinib) Combination for Patients with Advanced Renal Cell Carcinoma
Darmstadt, Germany and New York, US, May 14, 2019– Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: Canada Health | Cancer & Oncology | Carcinoma | Drugs & Pharmacology | Germany Health | Kidney Cancer | Merck | Pfizer | Renal Cell Carcinoma